← All trials
NCT04461353
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2020
- Primary completion
- Aug 17, 2020
- Completion date
- Aug 17, 2020
- First posted
- Jul 8, 2020
- Last posted
- Oct 8, 2020
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pulmoquine Therapeutics, IncLead sponsor
- Rockefeller UniversityOverall official - principal investigator
- Rockefeller UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.